Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of oral ICP-488 in primary Sjogren's syndrome
CTR20262835Phase 2Active
- Sponsor
- Innovent Biologics
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of icp-488 in Sjögren's syndrome (SS), sponsored by Innovent Biologics. Started Aug 2026; status: active.
02
Drugs
icp-488
03
Conditions
Sjögren's syndrome (SS)
Beyond the preview
Go deeper on CTR20262835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262835.